Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDNF and gene expression changes in major depressive disorder treated with fluoxetine versus cognitive-behavioral therapy
IRCT20190710044171N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluoxetine in major depressive disorder (MDD) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Clinical examination of patients, Age of onset of the disease and 3 more. Started Jun 2020; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20190710044171N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190710044171N1.